We focused on nilotinib, a second-generation TKI targeting Lyn, which has been previously shown to ameliorate mouse model phenotypes of PD and AD by improving autophagy [12, 21, 28], and has tested in 6 months phase II clinical trial in PD patients [49, 62]. Here, LYN is linked to Parkinson disease.